Koru Medical Systems (KRMD) Q1 2026: International Core Surges 35% as Pre-Filled Syringe Shift Accelerates
International expansion and pipeline execution drove a record first quarter for Koru Medical Systems, with pre-filled syringe conversions in Europe powering outsized growth and new drug partnerships signaling a step-change in addressable market. While gross margin faced tariff-related headwinds, management reiterated full-year guidance and highlighted a robust path to positive cash flow and double-digit revenue growth. Investors should focus on the compounding effect of Koru’s expanding platform, international market adoption, and pipeline advancement as the company transitions to new leadership this summer.
Summary
- Pre-Filled Syringe Adoption Drives International Outperformance: European conversions underpin rapid international revenue expansion and new market entry.
- Pipeline Progress Broadens Addressable Market: Multiple phase three trials and new drug submissions reinforce platform optionality beyond core immunoglobulin.
- Leadership Transition Maintains Strategic Continuity: Incoming CEO Adam Calbermatten signals unwavering focus on three-pillar growth model.
Business Overview
Koru Medical Systems (KRMD) develops and sells infusion systems for chronic and specialty drug delivery, with a recurring revenue model anchored by the Freedom Infusion System, consumables, and related accessories. The business is structured across three major segments: domestic core (U.S. SCIG, or subcutaneous immunoglobulin, therapy), international core (non-U.S. SCIG and emerging markets), and pharma partnerships (pipeline and clinical trial support for non-IG drugs). Revenue is generated from device sales, high-margin consumables, and collaborative agreements with pharmaceutical companies for new drug delivery solutions.
Performance Analysis
Koru delivered a record Q1, with total revenue up 22% year-over-year, driven by international core growth of 35% and domestic core growth of 12%. The international surge was powered by pre-filled syringe conversions in the EU and strong distributor orders in new geographies, highlighting the company’s ability to capitalize on market transitions and pharmaceutical partner initiatives. Domestic performance was anchored by new patient starts and competitive account conversions, reflecting both market share gains and the resilience of the recurring patient base.
Gross margin contracted to 61.5%, down 130 basis points, primarily due to higher production costs and tariff-related charges, partially offset by favorable geographic mix. Adjusted EBITDA approached breakeven, with net losses improving 33%, underscoring operating leverage despite ongoing R&D and commercial investment. Cash usage was minimal, and the company ended the quarter with $8.8 million in cash, maintaining access to an unused $10 million debt facility for additional flexibility.
- International Core Outpaces All Segments: Pre-filled syringe conversion in five EU markets catalyzed distributor orders, with further patient pull-through expected in subsequent quarters.
- Pharma Services Pipeline Delivers Stepwise Growth: PSP (pharma services and pipeline) revenue grew 166% on clinical trial activity, though management cautions on variability tied to trial milestones.
- Gross Margin Headwinds Remain Transient: Tariff and production timing impacts are expected to normalize, with full-year margin guidance maintained at 61% to 63%.
Management’s reiteration of full-year guidance, despite Q1 overperformance, reflects prudent caution around international adoption pacing and evolving macro risks, particularly in the Middle East and global supply chain.
Executive Commentary
"Q1 2026 was a record start to the year. We delivered $11.8 million in revenue, representing 22% growth over the prior year period. This reflects the strength and consistency of a recurring revenue model business built on the foundation of approximately 60,000 patients on the KORU platform."
Linda Tharby, Chief Executive Officer
"Our long-term targets are clear, and we are executing toward them with discipline. $100 million in revenue, accelerated double-digit revenue growth, gross margins above 65%, and EBITDA margins of 20% or greater. Achieving those targets requires continued focus on three things, growing our domestic market share, expanding internationally as we help to enable the pharmaceutical manufacturer vial to pre-filled syringe market conversion, and adding more drugs on our label."
Adam Calbermatten, President and incoming CEO
Strategic Positioning
1. International Expansion via Pre-Filled Syringe Conversions
Koru’s international strategy leverages pharmaceutical-driven transitions from vials to pre-filled syringes, especially in Europe, where five markets are now actively converting. This approach enables both upfront device sales and ongoing consumable pull-through, with distributor-led launches providing scale and operational leverage. Management expects variability in order timing but sees significant long-term runway as adoption deepens and new geographies come online.
2. Pipeline Diversification Beyond Immunoglobulin (IG)
The company’s pipeline now includes eight active non-IG drug opportunities, spanning oncology, nephrology, and rare diseases. Two collaborations advanced to phase three trials this quarter, and the 510K submission for deferoxamine adds another 200,000 annual infusion opportunity. Koru’s platform is positioned as a preferred delivery solution for specialty therapies, with each new drug representing incremental, often high-margin, recurring revenue potential.
3. Domestic Core Growth and Market Share Capture
In the U.S., Koru continues to outperform underlying SCIG market growth, driven by new patient starts, competitive conversions, and the addition of new drugs (such as Restigo and Empaveli) to its platform. The domestic business benefits from a stable, chronic patient base and expanding indications, with secondary immunodeficiency (SID) flagged as a future catalyst pending reimbursement expansion and clinical trial outcomes.
4. Operational Focus and Cost Discipline
Despite ongoing investment in R&D and commercial infrastructure, Koru maintained operating expense growth at 11% and minimal cash usage. Gross margin pressure from tariffs and production costs is being addressed through operational excellence initiatives and pricing strategies, with management targeting a return to margin expansion as new markets mature and scale efficiencies are realized.
5. Leadership Transition and Strategic Continuity
With CEO Linda Tharby stepping down and Adam Calbermatten taking the helm, the company is signaling continuity in its three-pillar growth strategy. The transition is described as smooth, with both outgoing and incoming leadership emphasizing execution discipline, pipeline advancement, and a clear path to the $100 million revenue milestone.
Key Considerations
Koru’s Q1 performance reflects both the scalability of its recurring revenue model and the optionality embedded in its expanding platform. The company’s ability to execute across multiple geographies and drug categories, while maintaining cost discipline and advancing its pipeline, positions it for durable growth—but also requires careful management of adoption pacing, regulatory hurdles, and external risks.
Key Considerations:
- Pre-Filled Syringe Conversion Pace: The cadence of international distributor orders and patient pull-through will be critical for sustaining revenue momentum and margin leverage.
- Pipeline Commercialization Timing: Phase three trial progress and regulatory submissions for non-IG drugs will shape future revenue mix and platform scale.
- Gross Margin Recovery: Tariff and supply chain pressures are expected to moderate, but ongoing monitoring is needed as new markets ramp.
- Leadership Execution Post-Transition: The CEO handoff to Adam Calbermatten will test continuity in strategy and operational discipline as the company targets ambitious long-term goals.
Risks
Key risks include the variable timing of international adoption, especially as distributor-led launches and reimbursement environments differ by geography. Tariff exposure and supply chain volatility could pressure margins if global macro conditions worsen. Pipeline execution is inherently uncertain, with regulatory and clinical trial outcomes dictating future revenue streams. Geopolitical instability, particularly in the Middle East, introduces additional unpredictability for certain distributor markets, though these currently represent a modest share of total revenue.
Forward Outlook
For Q2 2026, Koru expects:
- Continued ramp in international pull-through as pre-filled syringe conversions progress.
- Domestic core to sustain above-market growth with further patient starts and drug additions.
For full-year 2026, management reiterated guidance:
- Revenue of $47.5 to $50 million (15% to 22% growth)
- Gross margin of 61% to 63%
- Positive adjusted EBITDA and positive cash flow
Management highlighted:
- Back-half weighted revenue as new geographies scale and recent clearances contribute.
- Ongoing operational leverage and cost initiatives to support targeted margin recovery.
Takeaways
Koru’s Q1 outperformance and pipeline momentum reinforce the business’s leverage to both recurring revenue and new market expansion, but the durability of this growth will hinge on execution in international markets and successful commercialization of non-IG therapies.
- International Core as a Growth Engine: Pre-filled syringe conversions in Europe are the primary catalyst for outsized growth and are expected to drive further upside as adoption matures.
- Pipeline Optionality Expands TAM: Progress in non-IG collaborations and new drug submissions position Koru for a step-change in addressable market and future revenue diversity.
- Execution on Three-Pillar Strategy Remains Central: Investors should monitor leadership’s ability to advance all three growth vectors—domestic share, international expansion, and pipeline commercialization—while managing cost and regulatory risks.
Conclusion
Koru Medical Systems delivered a record first quarter, driven by international expansion and pipeline advancement, while maintaining a disciplined outlook and reiterating full-year guidance. As the company transitions to new leadership, the strategic foundation remains intact, with the next phase of growth hinging on international adoption, pipeline execution, and operational leverage.
Industry Read-Through
Koru’s accelerating traction in pre-filled syringe conversions serves as a bellwether for the broader infusion and specialty pharma device market, underscoring the importance of platform adaptability and pharma partnership alignment. The company’s ability to convert clinical collaborations into commercial revenue highlights a growing trend among device makers to embed themselves earlier in the drug development lifecycle, capturing value from both chronic and specialty indications. For peers in medtech and drug delivery, Koru’s international market strategy and pipeline-driven expansion offer a blueprint for scaling recurring revenue and broadening addressable market in a rapidly evolving therapeutic landscape.